Creative Medical Technology Holdings Inc (CELZ) Stock Price, Quote & News

Company Profile

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized super...

Industry: Biotechnology

Sector: Healthcare

Phone: 480 399 2822

Website: www.creativemedicaltechnology.com

Address:

211 East Osborn Road, Phoenix, United States

Kjstock Apr. 25 at 12:50 PM

$CELZ New SEC Filing Filed: Company: CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. CIK: 1187953 Symbol: CELZ Ticker: NASDAQ:CELZ Accession Number: 0001477932-26-002534 Form: 10-K/A Filed On: 2026-04-24 File Number: 001-41120 Film Number: 26895143 URL: https://1187953.ir365connect.com/secfilings Original URL: https://www.sec.gov/Archives/edgar/data/0001187953/000147793226002534/celz_10ka.htm

1 · Reply

ZTRADEZ_LLC Apr. 23 at 1:57 PM

(NASDAQ: $CELZ) Creative Medical Technology Holdings Inc WATCHING THIS NOW! ✅Float 3.65M Creative Medical Technology Holdings recently achieved its second WHO INN milestone, significantly strengthening its global regulatory position for its cell therapy pipeline. CELZ is a biopharma company focused on developing advanced cell therapies for conditions like chronic pain and diabetes. Communicated Disclaimer https://www.ztradez.net/communicated-disclaimer $BYND $BIRD

0 · Reply

JTE_Theta Apr. 23 at 1:45 PM

🚨 $CELZ | Clinical Momentum Building Creative Medical Technology Holdings is advancing regenerative medicine with multiple near-term catalysts in 2026. 🔬 ADAPT Trial (Chronic Back Pain) • Positive 180-day interim data • 79% of patients achieved meaningful pain & function improvement 🧬 Pipeline Progress • CELZ-201 targeting degenerative disc disease & Type 1 diabetes • FDA-cleared programs with Fast Track designation • H1 2026 topline data expected 🌍 Regulatory Milestones • WHO granted INN naming (olastrocel & etaroleucel), strengthening global positioning 🇺🇸 BioDefense Initiative • Regulatory approval to expand nationwide program supporting veterans exposed to burn pits With multiple clinical readouts ahead $CELZ is entering a potential inflection year ! CommunicatedDisclaimer:https://tinyurl.com/bdduhp5k

0 · Reply

Rasto2020 Apr. 21 at 12:20 AM

$CELZ it needs to hold $2 … it is known for large spikes . It could get to $4 , but …

1 · Reply

gteu3212 Apr. 17 at 8:57 PM

@wokazn any suggestions for a little prognose? $CELZ

3 · Reply

ka1954 Apr. 17 at 8:03 PM

$CELZ can we get a big pop in this finally? enough with slow and steady

1 · Reply

tonneke Apr. 17 at 7:27 PM

$CELZ 💪💪💪👍

0 · Reply

BottomFisher_ Apr. 17 at 3:36 PM

$CELZ update — this one is starting to get interesting again Creative Medical just locked in full enrollment for its Phase 2 ADAPT trial targeting chronic lower back pain — that’s a key de-risking step most small caps struggle to reach. Even more important, interim data already showed strong response rates + functional improvement… market hasn’t fully priced that in yet. They also hit their SECOND WHO INN milestone (Feb 2026) — that’s not fluff, that’s validation at the global level. Now the real catalyst: full Phase 2 data drop expected later this year. That’s where things can re-rate fast if results confirm earlier signals. Pipeline angle matters too — stem cell platform going after chronic pain + diabetes + immune disorders… we’re talking a TAM north of $100B. High risk, high reward setup — but this is exactly where asymmetric trades are born. Watching closely for volume + momentum shift

0 · Reply

chris_stocks Apr. 16 at 10:54 PM

$CELZ any idea of what the Target price for this is and how soon

1 · Reply

Peterb3346 Apr. 16 at 7:54 PM

$CELZ that was a big buy...

3 · Reply

Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain

Jan 6, 2026, 9:15 AM EST - 3 months ago

Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative

Dec 17, 2025, 9:15 AM EST - 4 months ago

Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point

Dec 2, 2025, 9:15 AM EST - 5 months ago

Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201

Oct 30, 2025, 9:15 AM EDT - 6 months ago

Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits

Oct 29, 2025, 9:00 AM EDT - 6 months ago

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds

Oct 27, 2025, 8:15 AM EDT - 6 months ago

Creative Medical Technology Holdings Issues Letter to Shareholders

Oct 7, 2025, 9:15 AM EDT - 7 months ago

Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs

Jul 17, 2025, 9:15 AM EDT - 10 months ago

Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells

Jul 11, 2025, 8:01 AM EDT - 10 months ago

Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling

Mar 20, 2025, 7:50 AM EDT - 1 year ago

Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain

Mar 6, 2025, 8:10 AM EST - 1 year ago

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds

Feb 14, 2025, 7:00 AM EST - 1 year ago

Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™

Feb 11, 2025, 9:25 AM EST - 1 year ago

Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program

Feb 5, 2025, 8:25 AM EST - 1 year ago

Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development

Jan 30, 2025, 9:25 AM EST - 1 year ago

Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain

Nov 13, 2024, 9:00 AM EST - 1 year ago

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

Jul 24, 2024, 9:00 AM EDT - 1 year ago

Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program

Jul 10, 2024, 8:30 AM EDT - 1 year ago

Creative Medical Technology Holdings Provides Corporate Update

Jun 24, 2024, 8:30 AM EDT - 1 year ago

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Mar 7, 2024, 9:15 AM EST - 2 years ago

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access

Mar 6, 2024, 7:00 AM EST - 2 years ago

Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy

Dec 20, 2023, 9:35 AM EST - 2 years ago

Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain

Oct 10, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain

Aug 24, 2023, 10:45 AM EDT - 2 years ago

What Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth?

Jul 14, 2023, 9:00 AM EDT - 3 years ago

The Immunotherapy Market is Expected to Surpass $351.56 Billion by 2030 - Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is Contributing to this Growth

Jul 13, 2023, 9:00 AM EDT - 3 years ago

Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update

Jun 28, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements

Jun 12, 2023, 8:01 AM EDT - 3 years ago

Creative Medical Technology Announces $2 Million Share Repurchase Program

Jun 9, 2023, 12:30 PM EDT - 3 years ago

Creative Medical Technology Holdings Announces Reverse Stock Split

May 31, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform

May 22, 2023, 8:30 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development

May 18, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line

Apr 12, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study

Apr 4, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update

Mar 23, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes

Mar 21, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz® Platform Development

Mar 7, 2023, 8:00 AM EST - 3 years ago

Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201

Feb 14, 2023, 8:00 AM EST - 3 years ago

Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects

Feb 8, 2023, 8:00 AM EST - 3 years ago

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

Nov 3, 2022, 7:30 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes

Oct 20, 2022, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line

Sep 26, 2022, 8:00 AM EDT - 3 years ago

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study

Jul 28, 2022, 7:30 AM EDT - 4 years ago

Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study

Jun 15, 2022, 8:30 AM EDT - 4 years ago

Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz® Immunotherapy Platform

Apr 29, 2022, 8:40 AM EDT - 4 years ago

Creative Medical Technology Announces $17 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 20, 2022, 8:30 AM EDT - 4 years ago

Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product

Apr 12, 2022, 8:30 AM EDT - 4 years ago

Creative Medical Technology to Showcase CaverStem® at American Urological Association Annual Meeting - Largest and Most Prominent Gathering of Urologists in the World

Mar 23, 2022, 10:15 AM EDT - 4 years ago

Why Creative Medical Technology Shares Are Soaring

Kjstock Apr. 25 at 12:50 PM

1 · Reply

ZTRADEZ_LLC Apr. 23 at 1:57 PM

0 · Reply

JTE_Theta Apr. 23 at 1:45 PM

0 · Reply

Rasto2020 Apr. 21 at 12:20 AM

$CELZ it needs to hold $2 … it is known for large spikes . It could get to $4 , but …

1 · Reply

gteu3212 Apr. 17 at 8:57 PM

@wokazn any suggestions for a little prognose? $CELZ

3 · Reply

ka1954 Apr. 17 at 8:03 PM

$CELZ can we get a big pop in this finally? enough with slow and steady

1 · Reply

tonneke Apr. 17 at 7:27 PM

$CELZ 💪💪💪👍

0 · Reply

BottomFisher_ Apr. 17 at 3:36 PM

0 · Reply

chris_stocks Apr. 16 at 10:54 PM

$CELZ any idea of what the Target price for this is and how soon

1 · Reply

Peterb3346 Apr. 16 at 7:54 PM

$CELZ that was a big buy...

3 · Reply

TheRealShortSqueezy Apr. 16 at 4:14 PM

$CELZ: Bullish Momentum Building After Prolonged Base Formation 📡🧬 Recent price action reflects tight consolidation, with buyers stepping in on dips and volume beginning to expand, suggesting early stage interest returning. Technical View: 🔹 Prolonged downtrend transitioning into sideways base 🔹 Higher lows forming within consolidation structure 🔹 Compression beneath resistance = potential breakout setup Key Levels to Watch: 🎯 $2.02 🟰 Key support / reclaim level 🎯 $2.35–$2.51 🟰 Near-term resistance zone 🎯 $2.74 🟰 Breakout confirmation level 🎯 $3.08–$3.34 🟰 Major supply area It will be interesting to keep on watch management next business update and press releases. Their data results could increase shareholder value significantly Communicated Disclaimer: http://tinyurl.com/Therealshortsq… Sector Peers: $VXRT $HOOK $BCDA $CAPR

0 · Reply

jcooptechit Apr. 16 at 4:06 PM

$CELZ UPTREND CONFIRMED AND $2.32 IS THE LAUNCHPAD CELZ has flipped bullish with higher lows and is now pressing a key breakout zone. 📊 Levels: ▫️ Demand: $1.95 – $2.05 (strong base) ▫️ Support: $2.10 – $2.20 ▫️ Pivot: $2.32: key level ▫️ Resistance: $2.50 → $2.72 📈 Structure tightening + momentum building: → Hold & push $2.32 → opens move to $2.50 / $2.72 → Break $2.72 → $3+ comes into play FAST → Backed by ongoing trials + upcoming clinical updates = catalyst fuel 👀 Watching closely as this is where momentum traders often step in. Communicated - Disclaimer: https://fh.bio/jcoop Sector Peers: $REGN $VRTX $ALNY $IONS

0 · Reply

WhoKnocks Apr. 16 at 3:24 PM

$CELZ 2️⃣ Estimating Burn Rate & Runway A conservative estimate based on filings and recent history: Quarterly burn: ~$1.2–1.7M Annualized burn: ~$5–7M Unless CELZ materially reduced spending (unlikely during active trials), the company typically carries less than one year of operational runway at any time. [msn.com], [tickernerd.com] 👉 This places the next capital raise window around H2 2026, with planning likely already underway.

0 · Reply

TheRealShortSqueezy Apr. 16 at 1:42 PM

🧬 $CELZ : A Tiny Biotech Taking a Shot at Huge Markets Creative Medical Technology Holdings is a regenerative medicine company developing stem cell therapies aimed at treating chronic pain, diabetes, and immune disorders by targeting disease at the source. Recent Milestones ✔️ Completed patient enrollment in the Phase 2 ADAPT trial for chronic lower back pain ✔️ Reported strong interim data with high response rates and improved function ✔️ Achieved second WHO International Nonproprietary Name milestone (Feb 2026), now with dual programs recognized globally Catalysts to Watch 🗓️ Full Phase 2 ADAPT data readout expected in 2026 🗓️ Potential follow up trial design or FDA discussions after data release 🗓️ Potential partnership or licensing activity as clinical data matures With clinical data emerging and multiple programs in play, CELZ is going after $100B+ markets. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyCELZ Sector Peers: $VXRT $HOOK $ATOS $CLRB

0 · Reply

griffinrc23 Apr. 16 at 1:41 PM

$CELZ is the NASDAQ ticker for Creative Medical Technology Holdings, Inc., a small-cap, commercial-stage biotechnology company focused on regenerative medicine, stem cell therapies, and immunotherapies. The company targets areas like immunotherapy, endocrinology (e.g., diabetes), urology (e.g., erectile dysfunction and female sexual health), neurology, and orthopedics (e.g., chronic lower back pain). Current Stock Snapshot (as of April 15–16, 2026 close) • Price: Approximately $2.32 (up ~5.45% on April 15; recent trading around $2.14–$2.32). • Market Cap: ~$8.5–8.6 million (micro-cap). • 52-Week Range: $1.504 – $6.25. • Volume: Recent daily ~43K–60K (avg. around 43K–63K). • Shares Outstanding: ~3.7 million. • Beta: ~1.0–2.0 (volatile). • P/E Ratio: N/A (negative earnings). • EPS (TTM): Around -$2.29 to -$2.52. http://creativemedicaltechnology.com Commincated Disclaimer: http://tinyurl.com/2c5ux6ux

0 · Reply

jcooptechit Apr. 16 at 1:33 PM

$CELZ AT A CLINICAL INFLECTION POINT AND DATA + MOMENTUM ALIGNING CELZ isn’t just a story anymore… it’s showing real clinical progress. 🧬 CELZ-201 (Back Pain | ADAPT Trial): ▫️ Phase I/II COMPLETE enrollment ▫️ Positive 180-day data ▫️ 79% patient improvement ▫️ No major safety concerns ▫️ FDA Fast Track Now entering data maturation + next-stage pathway 💥 THE ALPHA: ✅ Early efficacy ✅ Safety validated ✅ Massive market (chronic back pain) This is where small-cap biotech names can rerate FAST. Next catalysts: final data + regulatory progress + potential partnerships. 👀 Clinical validation + technical setup = one to watch closely Communicated - Disclaimer: https://fh.bio/jcoop Sector Peers/ Competitors: $MESO $VRTX $NVAX $MRNA

1 · Reply

BullTradeFinder Apr. 16 at 1:29 PM

$CELZ Is Curling, setting up for a move higher into 2.55+. Keep this name on watch. Communicated-Disclaimer https://docs.google.com/document/d/1e8SREkmmiEAl82sA1_iUWlDAzNlG14TLQVcJbfLO9oI/edit?usp=sharing

0 · Reply

uppons Apr. 14 at 6:20 PM

$CELZ sleeping giant

0 · Reply

ZTRADEZ_LLC Apr. 14 at 3:20 PM

$CELZ | LOVING THE UPWARD TREND HERE WATCHING THIS LONG-TERM HERE LOOK @ THAT VOLUME GAP ABOVE + THE 50 EMA HOLD Volume gap to $3.00 Communicated Disclaimer https://www.ztradez.net/communicated-disclaimer

0 · Reply

JTE_Theta Apr. 14 at 1:49 PM

🧬 $CELZ — The Sleeping Biotech Giant Creative Medical Technology Holdings Clinical stage biotech developing cutting edge stem cell & regenerative medicine therapies targeting chronic back pain, Type 1 diabetes, erectile dysfunction, and more. Trading at just $2.20 with massive catalysts ahead invertors are watching closely. 👀 Why $CELZ could pop in 2026 👇 🟢 ADAPT trial interim data showed 79% of patients hit clinically meaningful improvements in pain & function 🟢 FDA Fast Track designation secured for their lead therapy CELZ-201-DDT 🟢 Topline ADAPT results + Type 1 Diabetes data BOTH expected H1 2026 🟢 60+ patents, 6 billion+ clinical-grade cells already manufactured 🟢 $20B+ spinal disorders market by 2030 CommunicatedDisclaimer:https://tinyurl.com/bdduhp5k

0 · Reply

H177 Apr. 13 at 10:55 PM

$CELZ

0 · Reply

ZTRADEZ_LLC Apr. 13 at 3:18 PM

$CELZ | LOVING THE UPWARD TREND HERE Volume gap to $3 Communicated Disclaimer https://www.ztradez.net/communicated-disclaimer $UP $ONDS

0 · Reply

Market Cap	8.28M
Revenue (ttm)	10,000.00
Net Income (ttm)	-6.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-60,000.00%
Debt to Equity Ratio	0.00

Volume	19,300
Avg Vol	43,650
Day's Range	N/A - N/A
Shares Out	3.70M
Stochastic %K	45%
Beta	1.94
Analysts	Sell
Price Target	$20.00